Colchicine: Dosing, Contraindications, Drug Interactions, and Adverse Effects
For acute gout flares, use low-dose colchicine (1.2 mg followed by 0.6 mg one hour later) rather than high-dose regimens, as this provides equivalent efficacy with significantly fewer gastrointestinal side effects. 1, 2
Dosing Regimens
Acute Gout Flares
The FDA-approved regimen is 1.2 mg (two tablets) at the first sign of flare, followed by 0.6 mg (one tablet) one hour later, for a total of 1.8 mg over one hour 3. This low-dose approach is supported by strong evidence showing it is as effective as the older high-dose regimen (1.2 mg followed by 0.6 mg hourly for 6 hours) but with dramatically fewer adverse effects—specifically, diarrhea occurred in only 23% with low-dose versus 77% with high-dose colchicine 1, 4.
Colchicine should be initiated within 12 hours of flare onset for optimal efficacy 2. If a patient is already on prophylactic colchicine when a flare occurs, give the 1.2 mg loading dose followed by 0.6 mg one hour later, then wait 12 hours before resuming the prophylactic dose 3.
Gout Flare Prophylaxis
For prophylaxis during urate-lowering therapy initiation, use 0.6 mg once or twice daily (maximum 1.2 mg/day) 3. The 2017 EULAR guidelines recommend 0.5-1 mg/day, with dose reduction in renal impairment 2. Prophylaxis should continue for at least 6 months after starting urate-lowering therapy 2, 5, as mobilization of urate crystals during this period increases flare risk.
Familial Mediterranean Fever (FMF)
For adults with FMF, start with 1.2-2.4 mg daily, titrated in 0.3 mg increments to control disease while monitoring tolerability 3. The dose may be given once daily or divided into two doses. For pediatric patients:
- Ages 4-6 years: 0.3-1.8 mg daily
- Ages 6-12 years: 0.9-1.8 mg daily
- Ages >12 years: 1.2-2.4 mg daily 3
Notably, younger children may require higher weight-based doses (up to 0.07 mg/kg/day or 1.9 mg/m²/day in children under 5 years) compared to adolescents 6. The 2025 EULAR/PRES guidelines emphasize that the maximum adult dose is 3 mg daily 7.
Contraindications
Colchicine is absolutely contraindicated in patients with renal or hepatic impairment who are concurrently using strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) or P-glycoprotein inhibitors (e.g., cyclosporine) 1. This combination has resulted in fatal colchicine toxicity 2, 8.
Additional contraindications include:
- Severe renal impairment (colchicine and NSAIDs should be avoided) 2
- Patients receiving both strong CYP3A4 and P-gp inhibitors simultaneously
- Known hypersensitivity to colchicine
Drug Interactions
The most clinically significant interactions involve CYP3A4 and P-glycoprotein inhibitors, which can increase colchicine plasma levels dramatically and cause life-threatening toxicity including pancytopenia, multiorgan failure, and cardiac arrhythmias 8.
Strong CYP3A4 Inhibitors (Contraindicated or Require Major Dose Reduction)
When strong inhibitors like clarithromycin, ketoconazole, ritonavir, or atazanavir are necessary 3:
- Gout prophylaxis: Reduce from 0.6 mg twice daily to 0.3 mg once daily
- Acute gout: Reduce from 1.2 mg + 0.6 mg to 0.6 mg × 1 dose (no repeat for 3 days)
- FMF: Reduce maximum daily dose from 1.2-2.4 mg to 0.6 mg (may give as 0.3 mg twice daily)
Moderate CYP3A4 Inhibitors
With diltiazem, verapamil, erythromycin, or fluconazole 3:
- Gout prophylaxis: Reduce from 0.6 mg twice daily to 0.3 mg twice daily or 0.6 mg once daily
- Acute gout: Give 1.2 mg × 1 dose only (no repeat for 3 days)
- FMF: Reduce maximum to 1.2 mg daily
Neuromuscular toxicity has been specifically reported with diltiazem and verapamil combinations 2.
P-glycoprotein Inhibitors
Cyclosporine and ranolazine require the same dose reductions as strong CYP3A4 inhibitors 3. Fatal toxicity has been documented with cyclosporine 2.
Statin Interactions
Patients on statins with renal impairment face increased risk of neurotoxicity and muscular toxicity with colchicine 2. While recent data suggest colchicine concentrations increase with statin use, this does not consistently result in muscle adverse events in clinical practice 9. However, vigilance is warranted, particularly in older patients with reduced renal function.
Adverse Effects
Gastrointestinal Effects (Most Common)
Diarrhea, nausea, vomiting, abdominal cramps, and pain are the most frequent adverse effects 1. With the low-dose acute regimen, only 23% experience diarrhea compared to 77% with high-dose regimens 1. These effects are dose-dependent and typically resolve with dose reduction.
Serious Toxicity
Colchicine has a narrow therapeutic window; overdose can be fatal 7, 10. Toxicity typically progresses through three stages:
- Initial (0-24 hours): Gastrointestinal symptoms (nausea, vomiting, diarrhea, abdominal pain)
- Multiorgan dysfunction (24-72 hours): Bone marrow suppression, hepatic and renal failure, cardiovascular collapse
- Recovery or death (>72 hours): Alopecia, rebound leukocytosis 10
Neuromuscular Toxicity
Chronic colchicine use, especially with renal impairment or drug interactions, can cause myopathy, neuropathy, and elevated creatine kinase 2. This risk is heightened in patients on statins or with reduced renal function.
Hematologic Effects
Bone marrow suppression with pancytopenia can occur, particularly with drug interactions or overdose 8.
Renal Impairment Dosing
Patients with moderate renal impairment (eGFR 30-59 mL/min/1.73 m²) should receive 0.48-0.5 mg daily for prophylaxis, while those with severe impairment (eGFR 15-29 mL/min/1.73 m²) should receive 0.3 mg daily 11. The standard 0.6 mg daily dose results in supratherapeutic levels in 36% of patients with severe renal impairment, while 0.3 mg every-other-day results in subtherapeutic levels for 20-70% of the dosing interval 11.
For acute gout flares in renal impairment, do not repeat treatment more frequently than every 14 days 3.
Critical Clinical Pitfalls
Do not use high-dose colchicine regimens—they offer no additional efficacy and cause severe diarrhea in the majority of patients 1, 4
Screen all patients for drug interactions before prescribing—particularly macrolides, azole antifungals, and calcium channel blockers 8
Adjust doses in renal impairment—failure to do so results in toxicity or therapeutic failure 11
Monitor for intentional or accidental overdose—colchicine's narrow therapeutic index makes overdose potentially fatal 7, 10
Educate patients on early self-administration—colchicine is most effective when taken within 12 hours of flare onset 2
Do not interrupt urate-lowering therapy during acute flares—continue the prophylactic regimen 5